J J Lancaster, A Grijalva, J Fink, J Ref, S Daugherty, S Whitman, K Fox, G Gorman, L D Lancaster, R Avery, T Acharya, A McArthur, J Strom, M K Pierce, T Moukabary, M Borgstrom, D Benson, M Mangiola, A C Pandey, M R Zile, A Bradshaw, J W Koevary, S Goldman
There are nearly 65 million people with chronic heart failure (CHF) globally, with no treatment directed at the pathologic cause of the disease, the loss of functioning cardiomyocytes. We have an allogeneic cardiac patch comprised of cardiomyocytes and human fibroblasts on a bioresorbable matrix. This patch increases blood flow to the damaged heart and improves left ventricular (LV) function in an immune competent rat model of ischemic CHF. After 6 months of treatment in an immune competent Yucatan mini swine ischemic CHF model, this patch restores LV contractility without constrictive physiology, partially reversing maladaptive LV and right ventricular remodeling, increases exercise tolerance, without inducing any cardiac arrhythmias or a change in myocardial oxygen consumption...
November 25, 2023: Communications Biology